Extended Abstract Journal of Nephrology and Transplantation 2019
Vol.3 No.1

Euro Nephrology 2019: Antiproteinuric efficacy of cilnidipine as an add on therapy to Ramipril in patients of diabetic kidney disease- Aalia Tausif- Himalayan Institute of Medical Sciences

Aalia Tausif, Taruna Sharma, Shahbaj Ahmad and **Juhi Kalra**

Himalayan Institute of Medical Sciences, India

Diabetic Nephropathy is disabling complication of uncontrolled diabetes mellitus. Clinical proteinuria is a well-established marker of renal dysfunction. ACE-I or ARBs are the first choice in the management of proteinuria, but even at the maximum dose they fail to cease the progression of proteinuria. Hence additions of Calcium Channel Blocker (CCB) to the already prescribed ACE-I can be used to augment its antiproteinuric effect. Cilnidipine a dual L/N-type CCB dilates the afferent and efferent arterioles of the glomerulus decreasing the intraglomerular pressure and showing antiproteinuric effects. The present study was aimed to study the antiproteinuric efficacy of Cilnidipine as an add on therapy to Ramipril. This interventional study was conducted on 60 patients of both genders aged 18 years and above with diabetic nephropathy (Stage-1 to Stage 4) over a period of one year. Baseline urine protein creatinine ratio (UPCR), serum creatinine and the estimated glomerular filtration rate (eGFR) was recorded and repeated at 12 weeks, after addition of Cilnidipine (5-20 mg) daily dose to the ongoing treatment with Ramipril (2.5-20mg) daily dose. The end point was decrease in the UPCR levels. After 12 weeks of treatment with Cilnidipine, it was observed that there was a significant reduction in the UPCR (mean + SD) from 3.3+1.19 to 3.1+1.05 respectively ($p<0.05$).The serum creatinine also showed a significant reduction along with an increase in the eGFR levels ($p<0.001$). This study reveals that the addition of Cilnidipine to Ramipril in patients of Diabetic kidney disease was highly efficacious in preventing the progression of Diabetic nephropathy. Diabetic nephropathy (DN), otherwise called diabetic kidney disease, is the interminable loss of kidney work happening in those with diabetes mellitus. Diabetic nephropathy is one of the main sources of interminable kidney infection (CKD) and end-stage renal malady (ESRD) all around. Protein misfortune in the pee because of harm to the glomeruli may get enormous, and cause a low serum album in with coming about summed up body growing (edema)and result in the nephrotic condition. In like manner, the evaluated glomerular filtration rate (eGFR) may dynamically tumble from an ordinary of more than 90 ml/min/1.73m2to under 15, so, all in all the patient is said to have end-stage kidney disease (ESKD). It normally is gradually dynamic over years.

Pathophysiologic variations from the norm in DN start with long-standing ineffectively controlled blood glucose levels. This is trailed by various changes in the filtration units of the kidneys, the nephrons. (There are ordinarily around 750,000–1.5 million nephrons in every grown-up kidney). Initially, there is choking of the efferent arteriolesand expansion of afferent arterioles, with coming about glomerular fine hypertension and hyperfiltration; this bit by bit changes to hypofiltration over time. Concurrently, there are changes inside the glomerulus itself: these incorporate a thickening of the storm cellar layer, a broadening of the cut films of the podocytes, an increment in the quantity of mesangial cells, and an expansion in mesangial grid. This lattice attacks the glomerular vessels and produces stores called Kimmelstiel-Wilson knobs. The mesangial cells and lattice can logically grow and devour the whole glomerulus, closing off filtration.

The status of DN might be checked by estimating two qualities: the measure of protein in the pee - proteinuria; and a blood test called the serum creatinine. The measure of the proteinuria mirrors the level of harm to any despite everything working glomeruli. The estimation of the serum creatinine can be utilized to ascertain the evaluated glomerular filtration rate (eGFR), which mirrors the level of glomeruli which are done separating the blood. Treatment with an angiotensin changing over catalyst inhibitor (ACEI) or angiotensin receptor blocker(ARB), which expands the arterioleexiting the glomerulus, along these lines diminishing the blood pressure within the glomerular vessels, which may slow (yet not stop) movement of the malady. Three classes of diabetes drugs – GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors–are additionally thought to slow the movement of diabetic nephropathy.

Diabetic nephropathy is the most well-known reason for ESKD and is a genuine intricacy that influences around one fourth of grown-ups with diabetes in the United StatesAffected people with end-stage kidney illness regularly require hemodialysisand in the long run kidney transplantationto supplant the bombed kidney function. Diabetic nephropathy is related with an expanded danger of deathin general, especially from cardiovascular sickness. The infection movement of DN includes different clinical stages: Hyperfiltration, Microalbuminuria, Macroalbuminuria, Nephrotic Proteinuria to dynamic incessant kidney malady prompting end-stage renal sickness (ESRD). The harm is applied on all compartments of the kidney: The glomerulus, the renal tubules, the vasculature (afferent and efferent renal arterioles) and the interstitium. Renal fibrosis is the last regular pathway of DN. This fibrosis is a result of numerous instruments including renal hemodynamic changes, glucose digestion variations from the norm related

This work is partly presented at 23rd European Nephrology Conference October on 23-24, 2019 held at Rome, Italy

with oxidative worry just as fiery procedures and an overactive renin-angiotensin-aldosterone framework (RAAS).

The pathophysiology of DN is thought to include a cooperation among hemodynamic and metabolic factors.

Hemodynamic variables remember an expansion for fundamental and intraglomerular pressure, just as the over-initiation of the RAAS. Studies have demonstrated that in the setting of diabetes, different components animate the RAAS, which is one of the most significant pathways in DN pathophysiology. Because of the higher heap of separated glucose, there is an up-guideline in the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubules, which cotransports sodium and glucose over into flow. This prompts a reduction in the conveyance of sodium chloride to the macula densa in the distal tubules, advancing the arrival of renin and over-actuating RAAS. Hyperfiltration is perhaps the most punctual component of DN. A few instruments have been proposed to cause hyperfiltration. One of these components is that as glomeruli gets hypertrophied, filtration surface territory at first increments. Another conceivable system is that irregular vascular control in diabetic nephropathy prompts a decrease in afferent glomerular arteriolar opposition and an expansion in efferent glomerular arteriolar obstruction, prompting a net increment in renal blood stream (RBF) and glomerular filtration rate (GFR). Glomerular hyperfiltration and a deviant guideline of RAAS lead to expanded intraglomerular pressure, causing weight on the endothelial cells, the mesangial cells and the podocytes. This worsens the brokenness brought about by the metabolic impacts of hyperglycemia.